Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Introduces Updated Designer Drug and Oral Fluid Compendiums

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Webinars to highlight new applications for LC/MS, MS.

Agilent Technologies Inc. has introduced new application compendiums on designer drug testing and toxicology of oral fluids.

Also available is an expanded GC/MS Designer Drug Library. The only resource of its kind, this searchable library includes designer stimulants that are often marketed as "bath salts" as well as additional cannabinoid compounds.

In tandem with the release of these new resources, Agilent is sponsoring monthly webinars featuring industry experts who will discuss new LC/MS and MS applications for forensic detection and analysis of designer drugs and metabolites.

"Designer drugs-especially bath salts-continue to make headlines across the country," said Tom Gluodenis, Agilent's global marketing manager of Forensics and Toxicology.

Gluodenis continued, "The important resources we're introducing today, used in collaboration with our specialized GC/MS laboratory technologies, provide forensic practitioners, crime laboratories, and federal workplace drug-testing programs with cost-effective, end-to-end solutions for designer drug screening and analysis."

Designer drugs are formulated to get around existing definitions of illicit compounds. Once difficult to trace, these substances can now be quickly identified and analyzed using Agilent's GC/MS technologies.

Agilent's expanded application compendium, "Identification of Synthetic Cannabinoids in Herbal Incense Blends by GC/MS," contains information on 45 cannabinoids and describes how to facilitate rapid screening and identification of these marijuana-like compounds. A companion compendium, "Analysis of Designer Stimulants by GC/MS," describes the analysis of 30 stimulants.

Agilent developed these compendiums, and the expanded GC/MS Designer Drug Library, in collaboration with NMS Labs.

Screening oral fluid is an accurate and effective alternative to screening urine or blood. It provides many collection advantages, and samples can be more easily analyzed using highly sensitive enzyme immunoassays and LC-MS/MS instrumentation.

Agilent's updated oral fluid compendium, "Drugs and Metabolites in Oral Fluid: Immunoassay Screening and LC/MS/MS Confirmation and Quantification," is a comprehensive treatise on the detection of drugs of abuse in oral fluid, covering 100 drugs in 11 classes.

The compendium includes information on sample collection and preparation, immunoassay screening and LC/QQQ confirmation. It also reflects changes to the mandatory guidelines for Federal Workplace Drug Testing Programs, and contains protocols for all the newly recommended Schedule II prescription medications. Agilent developed the compendium in collaboration with Immunalysis Corp.

To download the application compendium "Drugs and Metabolites in Oral Fluid," visit Agilent's Forensics & Toxicology website.

Webinar Series for Forensic Practitioners

Throughout the year, Agilent will sponsor a monthly online educational series focusing on the analysis of designer drugs and drugs of abuse. Hosted by RTI International's online education service on www.ForensicEd.org, the webinars listed below will also be available for replay following the live events. Additional webinars will be announced at a later date.

Comprehensive Workflow for Screening and Confirmation of Drugs in Oral Fluids, now accessible for replay at Forensic Science Education: Dr. Christine Moore of Immunalysis Corp. discusses designer drug compendiums, oral fluids sample collection, preparation, drug extraction, immunoassay screening and LC/QQQ confirmation equipment.

LC/QQQ Screening for 300 Designer Drugs and Metabolites, Tuesday, Feb. 26 at 9 a.m. and 1 p.m. EST: Dr. Tony DiCaprio of Florida International University's-, Forensic Science Institute will describe current work focusing on the development of LC-QQQ-MS/MS-based methods for rapid screening of designer drugs in forensic analysis.

GC/MS and GC/QQQ Screening for 300 Designer Drugs and Metabolites, Thursday, April 18 at 9 a.m. and 1 p.m. EST: Dr. Jose Almirall, also of Florida International University's Forensic Science Institute, will focus on the expanded Designer Drug Library that FIU has developed in partnership with Agilent; discussion will also focus on the entire workflow for effective and rapid screening of designer drugs.

Webinar co-sponsor RTI International is the Center of Excellence for the United States National Institute of Justice. The upcoming webinars are part of RTI's specialized forensic education service, which provides online forensic science training and continuing education courses to practitioners in forensic science, law enforcement, medico-legal death investigation and forensic toxicology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Technologies and Waters Corporation Formalize Instrument Control Exchange
Agilent Technologies Inc. and Waters Corp have announced a formal agreement to exchange instrument controls to improve the productivity of customers who own software and instruments from both companies.
Wednesday, July 01, 2015
Agilent Technologies Launches New Products for Analyzing Biotherapeutics
Expanded AdvanceBio portfolio enables scientists to speed research and lower costs.
Thursday, June 25, 2015
Agilent to Focus on "Powerful Partnerships, Inspiring Results" at ASMS 2015
Company to introduce solutions enabling new standards in mass spectrometry, lab productivity.
Friday, May 29, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
Agilent Names Alacris Theranostics as Certified Provider of Target Enrichment Services
Customers receive consistent data quality, reproducibility and reliability.
Saturday, January 17, 2015
Benefits of SPE for the Analysis of Mycotoxins
Fast and cost-effective sample preparation is essential for the analysis of mycotoxins in food and feed.
Wednesday, January 14, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Technologies - Making Better GC Connections
Improving GC connections for reliable, robust and reproducible results.
Wednesday, December 24, 2014
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent, Baylor Open Mass Spec Center of Excellence
The new facility aims to boost metabolomics research at Baylor College of Medicine.
Friday, December 05, 2014
Agilent, MRM Proteomics Extend Agreement
Agreement expands on an existing collaboration established in 2012, allowing both organizations to bolster their combined proteomics solutions, comprising reagent kits, hardware and software.
Friday, July 25, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!